201 related articles for article (PubMed ID: 35786802)
21. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
[TBL] [Abstract][Full Text] [Related]
23. Comparative Study of Efficacy Between Cyclosporine and Alitretinoin in Patients With Chronic Hand Eczema.
Jang JH; Joh HC; Song CH; Kim KY; Jue MS; Ro YS; Ko JY
Dermatitis; 2024; 35(3):258-265. PubMed ID: 37870578
[No Abstract] [Full Text] [Related]
24. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
[TBL] [Abstract][Full Text] [Related]
25. Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations.
Kishimoto M; Deshpande GA; Fukui S; Komagata Y; Ohyama M; Kaname S
Expert Rev Clin Immunol; 2023 Jan; 19(1):19-35. PubMed ID: 36408603
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
Olbrich H; Sadik CD; Ludwig RJ; Thaçi D; Boch K
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189381
[TBL] [Abstract][Full Text] [Related]
27. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
28. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
[TBL] [Abstract][Full Text] [Related]
29. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
31. Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study.
Chiricozzi A; Dal Bello G; Gori N; Di Nardo L; Schena D; Caldarola G; Maurelli M; De Simone C; Girolomoni G; Peris K
J Dermatolog Treat; 2023 Dec; 34(1):2235041. PubMed ID: 37449324
[TBL] [Abstract][Full Text] [Related]
32. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors.
Gael M; Adam T; Mariano-Bourin M; Bursztejn AC
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1541-1551. PubMed ID: 35569006
[TBL] [Abstract][Full Text] [Related]
34. Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients.
Gao Z; Dou Y; Zhao P; Wang CJ; Zhang J
Dermatology; 2023; 239(4):658-663. PubMed ID: 37011607
[TBL] [Abstract][Full Text] [Related]
35. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
36. Current treatments for atopic dermatitis in Japan.
Miyano K; Tsunemi Y
J Dermatol; 2021 Feb; 48(2):140-151. PubMed ID: 33377547
[TBL] [Abstract][Full Text] [Related]
37. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
de Wijs LEM; Bosma AL; Erler NS; Hollestein LM; Gerbens LAA; Middelkamp-Hup MA; Kunkeler ACM; Nijsten TEC; Spuls PI; Hijnen DJ
Br J Dermatol; 2020 Feb; 182(2):418-426. PubMed ID: 31145810
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Dupilumab in Pediatric Patient With Prurigo Nodularis-Like Atopic Dermatitis.
Yiling Y; Ali K; Jiayang D; Qiu Y; Kai G; JinPeng S; Tianci X; Min C; Menghua L; Liming W
Dermatitis; 2023; 34(2):162-163. PubMed ID: 36917530
[No Abstract] [Full Text] [Related]
40. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
Francuzik W; Alexiou A; Worm M
Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
